Sen. Grassley seeks transparency in FDA review of heart health risks with diabetes drug
WASHINGTON --- Sen. Chuck Grassley has asked the Food and Drug Administration to respond to accounts that an agency-convened drug safety oversight board voted earlier this month to keep Avandia on the market by a one-vote margin amid agency considerations of a second warning for the drug label about heart attack risks.
Grassley said sources indicate the board vote occurred on October 2, so he’s also asking the FDA about the terms and conditions governing public notification with this sort of information.
The FDA first issued a heightened warning about Avandia and heart failure risk in August, following a May study that appeared in the New England Journal of Medicine regarding the drug’s cardiovascular risks.
“The Avandia case continues to present new rounds of questions about the way the FDA monitors and assesses drug risks and decides whether to let the public know about emerging risks,” Grassley said.
###
Next Article Previous Article
Recent News
- Wyden Statement at Finance Committee Vote on RFK Jr.'s Nomination to be HHS Secretary
- Wyden: Trump Tariffs Will Make Everything More Expensive, Solve Zero Problems and Harm American Farmers and Small Businesses
- Wyden Slams RFK Jr.'s Failure to Answer Basic Questions on Vaccines
- Wyden Demands Answers Following Report of Musk Personnel Seeking Access to Highly Sensitive U.S. Treasury Payments System
- Wyden, Finance Democrats Press RFK Jr. to Reject Big Pharma Pause on Medicare Negotiation